Re: Farmas USA
CPRX
Catalyst Pharmaceuticals (CPRX +0.2%) Q4 results: Revenues: $0; R&D Expense: $2.4M (+14.3%); SG&A: $1.6M (+166.7%); Net Loss: ($3.5M) (-150.0%); Loss Per Share: ($0.05) (-66.7%).
FY2014 results: Revenues: $0; R&D Expense: $10.1M (+24.7%); SG&A: $4.5M (+104.5%); Operating Loss: ($14.6M) (-41.7%); Net Loss: ($15.5M) (-27.0%); Loss Per Share: ($0.24) (+11.1%); Quick Assets: $35.6M (+80.7%).
No guidance given.
Sheff @SheffStation
$CPRX..$4.39..announced earnings. ($0.06) EPS. Beats estimates. Moving strong here! Catalysts on deck in Q2.
El estimado era ($0.07) de Thomson Reuters